William C Olson

Author:

William J. Olson

ISBN #:

0714631787

Author:

William J. Olson

ISBN #:

0813371198

Author:

William J. Olson

ISBN #:

0813380812

Author:

William J. Olson

ISBN #:

0813389690

Author:

William J. Olson

ISBN #:

0813399785

Author:

William J. Olson

ISBN #:

0824092732

Author:

William C. Olson

ISBN #:

0139144994

Author:

William C. Olson

ISBN #:

0139145079

US Patent:

6548636, Apr 15, 2003

Filed:

Feb 28, 2001

Appl. No.:

09/796202

Inventors:

Tatjana Dragic - Scarsdale NY
William C. Olson - Ossining NY

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
Aaron Diamond AIDS Research Centre - New York NY

International Classification:

A61K 3804

US Classification:

530328, 530324, 530325, 530326, 530327

Abstract:

This invention provides a compound comprising the structure: YDINYYTSE wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein represents from 0 to 13 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the P at position 19 and extending therefrom in the carboxy terminal direction; wherein represents an amino group or an acetylated amino group; wherein represents a carboxyl group or an amidated carboxyl group; wherein all of , Y,D,I,N,Y,Y,T,S,E and are joined together by peptide bonds; further provided that at least two tyrosines in the compound are sulfated.

US Patent:

6710173, Mar 23, 2004

Filed:

Jun 23, 2000

Appl. No.:

09/602864

Inventors:

James M. Binley - Brooklyn NY
Norbert Schuelke - New City NY
William C. Olson - Ossining NY
Paul J. Maddon - Scarsdale NY
John P. Moore - New York NY

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
Aaron Diamond AIDS Research Centre (ADARC) - New York NY

International Classification:

C07H 2104

US Classification:

536 2372, 4241881, 4242081

Abstract:

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

US Patent:

6908734, Jun 21, 2005

Filed:

Dec 19, 2002

Appl. No.:

10/323314

Inventors:

Tatjana Dragic - Scarsdale NY, US
William C. Olson - Ossining NY, US

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
Aaron Diamond AIDS Research Centre - New York NY

International Classification:

C12Q001/70
C12P021/06
C12N005/00
C07K016/00
A61K039/21

US Classification:

435 5, 435 691, 435325, 4353391, 53038835, 4242081

Abstract:

This invention provides a compound comprising the structure: θαYDINYYTSEβλ wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein α represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein β represents from 0 to 13 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the P at position 19 and extending therefrom in the carboxy terminal direction; wherein θ represents an amino group or an acetylated amino group; wherein λ represents a carboxyl group or an amidated carboxyl group; wherein all of α,Y,D,I,N,Y,Y,T,S,E and β are joined together by peptide bonds; further provided that at least two tyrosines in the compound are sulfated.

US Patent:

7022324, Apr 4, 2006

Filed:

Dec 21, 2001

Appl. No.:

10/032162

Inventors:

James M. Binley - Brooklyn NY, US
Norbert Schuelke - New City NY, US
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
John P. Moore - New York NY, US

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/21

US Classification:

4241881, 4242081

Abstract:

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

US Patent:

7479553, Jan 20, 2009

Filed:

Feb 18, 2004

Appl. No.:

10/780993

Inventors:

James M. Binley - Brooklyn NY, US
Norbert Schuelke - New City NY, US
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
John P. Moore - New York NY, US

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
Aaron Diamond AIDS Research Centre (ADARC) - New York NY

International Classification:

C07H 21/04
A61K 39/21

US Classification:

536 2372, 4242081

Abstract:

This invention provides a DNA which upon transcription produces an RNA encoding a modified HIV-1 gp140 polypeptide, which polypeptide upon cleavage produces a modified gp120 and a modified ectodomain of gp41 which together form a complex exhibiting enhanced binding to HIV-1 neutralizing antibodies and reduced binding to HIV-1 non-neutralizing antibodies, wherein the modifications comprise an A492C mutation in gp120 and a T596C mutation in gp41, said mutations being numbered by reference to the HIV-1 isolate JR-FL, and resulting in a disulfide bond between gp120 and ectodomain gp41 which stabilizes the otherwise non-covalent gp120-gp41 interaction.

US Patent:

7592014, Sep 22, 2009

Filed:

Oct 28, 2005

Appl. No.:

11/261390

Inventors:

James M. Binley - Brooklyn NY, US
Norbert Schuelke - New City NY, US
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
John P. Moore - New York NY, US

Assignee:

Progenics Pharmaceuticals Inc. - Tarrytown NY
Aaron Diamond Aids Research Centre (ADARC) - New York NY

International Classification:

A61K 39/21

US Classification:

4242081

Abstract:

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

US Patent:

7850971, Dec 14, 2010

Filed:

Mar 21, 2003

Appl. No.:

10/395894

Inventors:

Paul J. Maddon - Scarsdale NY, US
Gerald P. Donovan - New York NY, US
William C. Olson - Ossining NY, US
Norbert Schuelke - Dedham MA, US
Jason Gardner - Merseyside, GB
Dangshe Ma - Millwood NY, US

Assignee:

PSMA Development Company, LLC - Tarrytown NY

International Classification:

A61K 39/00

US Classification:

4241851, 4241931, 4241941, 4242771, 530350, 435183

Abstract:

The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

US Patent:

8114965, Feb 14, 2012

Filed:

Nov 7, 2007

Appl. No.:

11/983372

Inventors:

Paul J. Maddon - Scarsdale NY, US
Gerald P. Donovan - New York NY, US
William C. Olson - Ossining NY, US
Norbert Schuelke - Dedham MA, US
Jason Gardner - Merseyside, GB
Dangshe Ma - Milwood NY, US
Jaspal S. Kang - Surrey, CA
Larry Green - San Francisco CA, US

Assignee:

PSMA Development Company, LLC - Tarrytown NY
Amgen Fremont Inc. - Fremont CA

International Classification:

C07K 16/18

US Classification:

5303871, 5303917, 5303873, 5303877, 5303888, 5303913, 536 235, 4353201, 435325, 435 691, 435328, 435330

Abstract:

The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.